

Contents

List of contributors	xi		
Preface	xv		
1. Autologous blood: platelet-rich plasma and platelet-poor plasma	1		
ALBERTO GOBBI, KATARZYNA HERMAN, IGNACIO DALLO, LEANDRA BIZZOCO AND MELANIO ACOSTA IV			
Introduction	1		
Composition	2		
Platelet-rich fibrin	3		
Fibrin functions in regeneration	4		
Applications in orthopedics	5		
Meniscus healing	6		
Tendon healing	6		
Platelet-rich plasma in muscle healing	6		
Platelet-rich plasma in cartilage	7		
Conclusion	8		
References	9		
2. Defining, measuring and optimizing platelet-rich plasma	13		
SHANE A. SHAPIRO, JOSHUA M. ROMERO AND JENNIFER R. ARTHURS			
Defining platelet-rich plasma	13		
Commercial system platelet-rich plasma variability	15		
Proposed platelet-rich plasma classifications	16		
Quantifying platelet-rich plasma	17		
Benchside analysis point of care	19		
Future directions	20		
References	20		
3. Optimal use of platelet-rich plasma and platelet-poor plasma	23		
ANJAY K. BATRA, CHRISTOPHER M. BRUSALIS, JOHNATHON MCCORMICK, HARKIRAT JAWANDA, ZEESHAN KHAN, SACHIN ALLAHABADI, GARRETT R. JACKSON AND JORGE CHAHLA			
Introduction	23		
Platelet-rich plasma and platelet-poor plasma: overview	24		
Muscle healing	24		
Common clinical applications	25		
Rotator cuff disease	25		
Ulnar collateral ligament injuries			26
Hip osteoarthritis			27
Knee osteoarthritis			27
Achilles tendinopathy			28
Summary			28
References			28
4. Where orthobiologics started: what are mesenchymal stem cells?			31
GARRETT R. JACKSON, DERRICK M. KNAPIK, FELICITAS ALLENDE, DANIEL J. KAPLAN, JORGE CHAHLA AND KENNETH R. ZASLAV			
Introduction			31
Orthobiologics: a historical overview			32
What are mesenchymal stem cells?			32
What mesenchymal stem cells are not			33
Orthopedic applications of mesenchymal stem cells			33
Conclusion			35
References			35
5. Bone marrow-derived mesenchymal stromal cells			39
MIRANDA G. MANFRE, ABDULAZIZ F. AHMED, DANIEL J. STOKES AND RACHEL M. FRANK			
Introduction			39
Harvest and preparation			40
Senescence			41
Regulations			42
Bone marrow-derived mesenchymal stromal cells versus concentrated bone marrow aspirate			42
Uses			42
Challenges for clinical application			44
Conclusion			45
Social media			45
References			45
6. Defining, optimizing, and measuring bone marrow aspirate and bone marrow concentrate			47
IGNACIO DALLO, PEDRO BERNÁLDEZ, GABRIEL SILVA SANTOS, JOSE FABIO LANA AND PETER A. EVERTS			
Introduction			47
Bone marrow extraction method			48
Overview of bone marrow harvesting guidance techniques			49

Differences between bone marrow aspirate and bone marrow concentrate	52	Practical considerations	104
Literature summary of results		Limitations and future directions	104
Bone marrow application in osteoarthritis	55	Conclusion	105
Conclusion	57	Disclosure statement	105
References	58	References	105
7. Optimal clinical use of bone marrow aspirate and bone marrow aspirate concentrate	61	11. Basic science and preclinical evidence for amniotic membrane – derived allografts in orthobiologics	111
SHAYNE R. KELLY, CLAYTON W. NUELLE AND SETH L. SHERMAN		HIROTAKA NAKAGAWA, ALBERTO J. PANERO, XIAOFEI QIN, OLUSEUN A. OLUFADE AND WALTER I. SUSSMAN	
Introduction	61	Introduction	111
Patient selection	62	Sources and isolation of placental-derived orthobiologics	112
Clinical uses/outcomes	62	Preclinical studies using amniotic membrane-derived products	113
Potential complications	69	Challenges and limitations of using amniotic membrane-derived orthobiologics	116
Conclusion	70	Conclusion	118
References	70	References	118
Further reading	72		
8. Adipose tissue-derived stromal/stem cells	73	12. Defining, optimizing, and measuring amniotic/placental mesenchymal stem cells	121
J.V. KORPERSHOEK, K.L. LYDON AND D.B.F. SARIS		IGNACIO PASQUALINI, MICHAEL D. DUBLÉ AND LUCIANO A. ROSSI	
Introduction	73	Anatomy and function	121
Chondroinduction by adipose tissue-derived stromal/stem cells	77	Formulation	122
Immunomodulation by adipose tissue-derived stromal/stem cells	77	Effects of use	122
Conclusion	78	Conclusion	125
References	79	References	126
9. Defining, optimizing, measuring, and utilizing adipose, MFAT, etc.	81	13. Optimal clinical use of amniotic/placental mesenchymal stem cells	129
ALEXANDER N. BERK, KYLE K. OBANA, WILLIAM M. CREGAR, DAVID P. TROFA, CLAUDE T. MOORMAN III AND BRYAN M. SALTZMAN		FARAH S. HUSSAIN, WALTER I. SUSSMAN AND OLUSEUN A. OLUFADE	
Introduction	81	Introduction	129
Adipose as a source of stem cells	82	History and basic science of birth tissue products	129
Mechanism of adipose function	84	Advantages and disadvantages of using amniotic/placental mesenchymal stem cells	130
Preparation of adipose stem cells	84	Current evidence of successful clinical use of amniotic/placental mesenchymal stem cells	131
Clinical application	86	Future directions and challenges for the clinical use of amniotic/placental-derived allografts	136
Limitations and shortcomings	90	Conclusion	137
Next steps and future directions	91	References	137
Conclusions	91		
References	91		
10. Optimal clinical use of adipose mesenchymal stromal cells	97	14. Synovial mesenchymal stem cells	141
ALEXIS J. BATISTE, DANIEL J. STOKES, MIRANDA G. MANFRE, GARWIN CHIN AND JASON L. DRAGOO		JACOB SINGER, NOAH KNEZIC, GRETA GOHRING, OLIVIA FITE, JEFF CHRISTIANSEN AND JOHNNY HUARD	
Introduction	97	Introduction	141
Biology of adipose-derived mesenchymal stromal cells	98	Background	142
Clinical use of adipose-derived mesenchymal stromal cells	98	The synovium	143

Role of mesenchymal stem cells in cartilage regeneration	144	19. The changing regulatory environment: regulations and restrictions	215
Synovial mesenchymal stem cells	147	SUSAN J. DRAPEAU AND SCOTT P. BRUDER	
Conclusion	149	Introduction	215
Future directions	150	Tissue regulations	215
Disclosures	150	Beyond tissue products: minimal manipulation, homologous use, and carrier impact	216
References	150	Practice of medicine	217
		Return to product regulation	217
15. Peripheral blood stem cells	155	References	219
ADAM W. ANZ, KHAY-YONG SAW, CAROLINE SIEW-YOKE JEE, MOHAMMADREZA ABBASIAN AND KEVIN B. JOHNSON		Further reading	219
Introduction	155		
Developmental perspective hematology oncology	156	20. Bioscaffolds for osteochondral injuries of the knee	221
Developmental background for cartilage repair	156	D. ALTOMARE, B. DI MATTEO, E.M. BERTOLINO, P. QUEIRAZZA AND E. KON	
Food Drug Administration pathway	162	Articular cartilage repair with bioscaffolds	221
Expanding indications for peripheral blood stem cells	163	Agili-C™ (Cartiheal Ltd., Israel)	223
Conclusions	176	Surgical technique and rehabilitation protocol	224
References	176	MaioRegen® (Fin-Ceramica S.p.A., Faenza, Italy) ¹⁰	226
		Autologous matrix-induced chondrogenesis	
16. Orthobiologics—growth factors and mediators	179	Chondro-Gide (Geistlich)	227
ALEXANDER BUMBERGER, CHILAN B.G. LEITE, SERCAN YALCIN AND CHRISTIAN LATTERMANN		Current literature available for synthetic grafts	229
Introduction	179	Conclusions	231
Growth factors	179	References	231
Future perspectives	185		
Conclusion	185	21. Orthobiologics on the horizon	235
References	185	MICHAEL M. CHAU AND BERT R. MANDELBAUM	
		Introduction	235
17. Orthobiologics in the procedure room—who, what, where, when, and how	191	Biological pathways as therapeutic targets	235
JEREMY A. ALLAND		Advancement of existing approaches	238
Introduction	191	Emerging therapeutic strategies	242
Platelet-rich plasma	191	Conclusion	245
Bone marrow aspirate concentrate	192	References	245
Adipose	200		
Amnion	200	22. Complications associated with orthobiologics	249
Conclusion	201	ANTONIO MADRAZO-IBARRA AND SCOTT A. RODEO	
References	201	Introduction	249
		Complications associated with cell therapies	250
18. Orthobiologics in the operating room—who, what, where, when, and how	203	Incidence of complications	251
KATIE MCMORROW, RYAN QUIGLEY, SACHIN ALLAHABADI, LANDON FRAZIER AND BRIAN J. COLE		Management of complications	252
Introduction	203	Prevention	252
Surgical techniques	203	Conclusion	253
Specific indications in the orthopedic operating room	209	References	253
Conclusion	212	Further reading	254
References	213	Index	255